Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;21(6):e70423.
doi: 10.1002/alz.70423.

Response to the letter titled "Targeting dementia prevention with semaglutide: the case for APOE4 homozygotes"

Rong Xu  1
Affiliations

Response to the letter titled "Targeting dementia prevention with semaglutide: the case for APOE4 homozygotes"

Rong Xu. Alzheimers Dement. 2025 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no conflicts of interest. Author disclosures are available in the supporting information.

Similar articles

See all similar articles

References

    1. Wang W, Wang Q, Qi X, et al. Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real‐world data in the US. Alzheimers Dement. 2024;20(12):8661‐8672. doi: 10.1002/alz.14313 - DOI - PMC - PubMed
    1. Serrano‐Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021;20(1):68‐80. - PMC - PubMed
    1. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission. Lancet. 2024;404(10452):572‐628. - PubMed
    1. Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138‐150. - PMC - PubMed
    1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834‐1144. - PubMed

LinkOut - more resources